Fast Locator 2011-2012: Dr. Reddy's Laboratories Inc. - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Dr. Reddy's Laboratories Inc.

The need to access emerging markets with new, cost-effective drugs, the reduction of NCEs that have been introduced to the market, the diminishing Blockbuster product model, and the far more complicated Life Cycle Management programs are just some of the new and ever-changing challenges that innovative pharmaceutical companies face in today's environment.

This is amplified by the increasing cost pressures from Healthcare payers for both governments and health care providers alike.

However, what has remained unchanged in the industry is the need to deliver high-quality, efficacious, and cost-effective medicine to patients while delivering high-value returns to the investors.

Even the emerging markets are demanding access to new and effective treatments at the same time as the rest if the established markets, but at a price which makes the products affordable to them.

CPS is able to help these innovator companies by offering innovative solutions through cost-effective development and manufacturing as well as with cutting edge science. It is by delivering solutions to the problems that the innovators encounter where CPS brings value.

Because of Dr. Reddy's experience in delivering high-quality, cost-effective medicines across the globe, CPS has the proven skill set to help the innovator forge their way through these new and serious challenges. We believe that only through intensified collaborations, we are able to address these external forces.


Regions where services are provided:

Asia, North America, Europe, Latin America.

Outsourcing services provided:

Development and Phase I/II CTM

  • Biocatalysis
  • Borane chemistry
  • Bromine chemistry/bromination
  • Carbohydrate chemistry
  • Cryogenics (lower-temperature reactions)
  • Chemocatalysis
  • Drug delivery
  • Injectible products development
  • Solid dose development
  • Process development-small molecule

Commercial Manufacturing

  • API and advanced intermediates (CGMP, small molecules)
  • Cyanide chemistry
  • Fluorination
  • Heterocyclic chemistry
  • High-potency or high-containment manufacturing
  • Injectables
  • Solid dosage forms

Analytical Services

  • Chemistry and stability
  • Hydrazine chemistry
  • Lithium chemistry
  • Microbiology
  • Nitration
  • Organometallic chemistry
  • Particle characterization

API Production Technologies

  • Acetylenic chemistry
  • Acid Chlorides
  • Acylation Prostaglandins
  • Amidation
  • Amino acids and analogs
  • Asymmetric synthesis or chiral chemistry
  • Azide chemistry
  • PEGs
  • Phosgenation
  • Steroids
  • Sulfonation



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here